logo
Peter Thiel on Whether He's Ushering in the Antichrist: Um, Uhh, Buh, Um Uhh, th th, Uhhhh

Peter Thiel on Whether He's Ushering in the Antichrist: Um, Uhh, Buh, Um Uhh, th th, Uhhhh

Gizmodo27-06-2025
Peter Thiel has been talking about the Devil a lot lately. Over the past few years, the eccentric tech billionaire has made it a habit of showing up at events sponsored by Christian organizations, where he has proceeded to espouse a bizarre brand of New Age-y faith. The tech magnate's preoccupation with God has only become more prominent as time has passed. During a recent appearance on the Hoover Institution's podcast, Thiel went on at length about his views on Apocalypse, Armageddon, and, pivotally, the Antichrist, who he feels could usher in the end of the World.
This week, an interview with New York Times columnist Ross Douthat gave Thiel yet another opportunity to wax on about the Evil One, though the conversation ultimately did not go exactly the way the billionaire wanted it to. When questioned by Douthat about what sort of qualities the Antichrist might have, he gave a very odd answer. It was, in part:
…perhaps we should also talk about the risk of another type of a bad singularity, which I would describe as the one-world totalitarian state. Because I would say the default political solution people have for all these existential risks is one-world governance. What do you do about nuclear weapons? We have a United Nations with real teeth that controls them, and they're controlled by an international political order. And then something like this is also: What do we do about A.I.? And we need global compute governance. We need a one-world government to control all the computers, log every single keystroke, to make sure people don't program a dangerous A.I. And I've been wondering whether that's going from the frying pan into the fire.
Thiel's suggestion seems to be that, if political organizations attempt to regulate the kinds of technology that he is invested in, they may actually be doing the Devil's work. These so-called religious views are obviously interesting for how closely they hew to the billionaire's political and economic interests. In the Palantir founder's eyes, Satan's vicar on Earth will be a loud supporter of stuff like nuclear non-proliferation, international law, and the regulation of AI. Later in the conversation, Thiel also suggested that the Antichrist could very well be someone like Greta Thunberg—in other words, a prominent social activist who cares less about stuff like profit margins and stock value and more about climate change and dead Palestinians.
But is Thiel's preoccupation with supernatural evil even real? Frankly, it's unclear whether the billionaire is just a liar or a guy whose head is crammed so far up his ass that day looks like night and a peaceful global order unperturbed by nuclear war looks like the work of the Devil. If we start from the presumption that most people aspire to be the hero of their own story, and that Thiel is one of those people, and that he feels that his creepy technocratic endeavors are actually a force for good in the world instead of an obvious pox on humanity, then it would be safe to assume that he also feels that anything that gets in the way of those endeavors is decidedly not good—or, in his own words, the work of the 'Antichrist.'
Anyway, later in Douthat and Thiel's conversation, the subject turned, again, to the Antichrist, and Douthat, to his credit, stuck the billionaire's feet to the fire somewhat. Douthat noted that, given Thiel's own investments and activities, it could very well be that he, himself, was laying the groundwork for his professed enemy. Douthat asks:
You're an investor in A.I. You're deeply invested in Palantir, in military technology, in technologies of surveillance and technologies of warfare and so on. And it just seems to me that when you tell me a story about the Antichrist coming to power and using the fear of technological change to impose order on the world, I feel like that Antichrist would maybe be using the tools that you are building. Like, wouldn't the Antichrist be like: Great, we're not going to have any more technological progress, but I really like what Palantir has done so far. Isn't that a concern? Wouldn't that be the irony of history, that the man publicly worrying about the Antichrist accidentally hastens his or her arrival?
Thiel's response was typical of his interviews: he stammered and sweated and looked like his face was going to fall off.
That awkward moment Peter Thiel realized he might be the very Antichrist he warned about pic.twitter.com/D9JvGARDtD
— Mykhaïlo Golub (@golub) June 27, 2025After an uncomfortably long period of time that mixed silence, stammering, and sweat, Thiel responded: 'Look, there are all these different scenarios. I obviously don't think that that's what I'm doing.'
Douthat assured the billionaire tycoon that he didn't think that's what was happening, but he was hoping to get a better picture of 'how you get to a world willing to submit to permanent authoritarian rule.'
At that point, it's possible that the Holy Spirit took the wheel as Thiel began to incoherently ramble about Thessalonians 5:3, the FDA, nuclear weapons regulations, Argentina, cultural stagnation, and historical predetermination. It's all a bit much.
The internet subsequently had fun with the exchange, noting the possibility that Thiel, himself, might actually be a modern-day Damien. 'That awkward moment Peter Thiel realized he might be the very Antichrist he warned about,' one user wrote. Another user, meanwhile, referred to the venture capitalist as 'Satan.'
Though he may share more than a passing resemblance to the Dark Lord, it seems pretty clear that Thiel could never be a serious contender for that role. That's because, unlike the honey-tongued underworld spawn that the Bible has long prophesied, Thiel is a complete verbal train wreck. Every interview with him—beset as they are by stammering and monotone intonations—is difficult to listen to. The Antichrist is supposed to be a compelling speaker, with the charm to cut across diverse constituencies. Entirely without rizz, Thiel obviously doesn't fit the profile. Donald Trump, on the other hand…
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Leach International Corporation Approves FDH Electronics Brand Stealth Aerospace as an Authorized Channel Partner for the Commercial Airline and MRO Markets
Leach International Corporation Approves FDH Electronics Brand Stealth Aerospace as an Authorized Channel Partner for the Commercial Airline and MRO Markets

Yahoo

time6 minutes ago

  • Yahoo

Leach International Corporation Approves FDH Electronics Brand Stealth Aerospace as an Authorized Channel Partner for the Commercial Airline and MRO Markets

Commercial aviation industry to benefit from access to Leach's trusted product lines through a reliable, scaled and independent distribution partner FDH Electronics & Leach Aerospace OKLAHOMA CITY, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Oklahoma-based FDH Electronics, a unified FDH Aero division focused solely on serving the mil-aero market's electronic component needs, is pleased to announce that its aftermarket division, Stealth Aerospace, has been named as an approved distribution channel by Leach International Corporation to support commercial airline and MRO customers. This strategic partnership builds on the companies' long-standing relationship and reinforces their shared commitment to deliver best-in-class service, product availability and technical support to the commercial aviation aftermarket sector. Alon Glickstein, Vice President at FDH Electronics, commented: 'We are incredibly proud to have established this partnership with Leach International. Their long-standing reputation for high-reliability products fits perfectly with our mission at FDH Electronics — to provide our customers with exceptional service, technical support, and inventory availability that meets their evolving needs.' Leach International, a leading manufacturer of advanced electrical switches, relays, and power distribution components for the aerospace and defense markets, sees this partnership as a key step toward strengthening its presence in the aftermarket segment. Justin Coates, Vice President of Sales & Marketing at Leach International Corporation, added: 'This agreement with FDH Electronics' Stealth Aerospace division ensures that Leach's products will be supported with an incredibly high level of service. Their proven performance in the aerospace aftermarket gives us full confidence that customers will benefit from rapid access to inventory, technical insight, and dedicated aftermarket expertise.' This announcement marks a new chapter in aftermarket excellence and provides the commercial aviation industry with access to Leach's trusted product lines through a specialized and reliable distribution partner. About FDH ElectronicsFDH Electronics is a global one-stop shop with one of the most expansive inventory levels in the industry, built on FDH Aero's industry-leading supply chain solutions. It supplies a variety of interconnect, wire and cable, and electromechanical components for the aerospace, defense, and space markets. FDH Electronics is your go-to resource for value-added connectors, 1553 Data Bus interconnect products, custom harnesses, high-performance aerospace-grade wire and cable, and high-frequency RF connectors. When you need critical interconnect or electromechanical components, you can rely on FDH Electronics to deliver. To search by part number, please visit: Contact:Heather RosenowExecutive Vice President, Marketing & Communicationsmediarelations@ About Leach International CorporationLeach International Corporation has been a leader in aerospace switching and control technology since 1919. Leach designs and manufactures high-reliability relays, contactors, and power distribution systems for aerospace, defense, and industrial applications. Contact:relayed@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Snap Stock Plunged After Earnings. Buy the Dip?
Snap Stock Plunged After Earnings. Buy the Dip?

Yahoo

time6 minutes ago

  • Yahoo

Snap Stock Plunged After Earnings. Buy the Dip?

Key Points Sponsored Snaps are showing strong engagement and conversion gains. Subscription revenue from Snapchat+ is growing quickly from a small base. Heavy stock-based compensation and dilution keep valuation concerns high. 10 stocks we like better than Snap › Snap (NYSE: SNAP), the parent company of social media platform Snapchat, took a hard hit following its second‑quarter earnings release earlier this month. Shares tumbled, driven by worries about slowing growth, execution missteps, and a worsening net loss. But dig deeper, and the underlying narrative is more nuanced; there were a lot of positives in the report, too. Revenue and users continue to grow at a robust rate, free cash flow has turned positive year over year, and new ad formats, such as sponsored Snaps, are demonstrating real engagement traction. Given the mix of good and bad in its underlying business and the stock's recent sell-off, it makes sense to check whether the shares have been pushed into oversold territory. Let's look at what changed in the business and what it might mean for investors today. Momentum in key areas Snap reported second-quarter revenue of $1.345 billion, marking a 9% gain from a year earlier. Further, the lifeblood of the company -- user activity -- performed exceptionally well. Daily active users (DAUs) rose 9% to 469 million, while monthly active users (MAUs) climbed 7% to 932 million. Operating cash flow reached $88 million, and free cash flow came in positive at $24 million, a notable reversal from the previous year, when the company burned cash. Still, Snap posted a net loss of $263 million (wider than a net loss of $249 million in the year-ago quarter), and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) slid lower on a year-over-year basis to $41 million, underscoring that profitability remains out of reach. An ad platform glitch -- where auction settings pushed some campaigns to clear at unusually low prices -- weighed on performance early in the quarter. Snap reversed the change mid-period, and management said that advertiser activity is of my favorite data points to support the bull case: On the diversification front, "other revenue" -- primarily from subscriptions like Snapchat+ -- grew 64% year over year, and Snapchat+ subscribers rose roughly 42%, nearing 16 million. One of the quarter's most promising developments was sponsored Snaps -- video ads delivered directly into users' inboxes. Snap co-founder Evan Spiegel said in the company's second-quarter earnings call that after a user opens a sponsored Snap from their chat feed, they "exhibit significantly higher engagement per full-screen ad view, driving a 2x increase in conversion, a 5x increase in click-to-convert ratios and a 2x increase in website dwell times compared to other inventories. That signals a powerful new lever for monetizing deeply engaged the company's fast-growing subscription business, advertising revenue growth trends after the glitch was addressed, and momentum in sponsored Snaps, management guided for continued top-line growth in Q3. Valuation remains a concern Despite a handful of promising trends at Snap, valuation remains troubling. The company has long leaned on equity dilution and stock-based compensation to fund growth. While Q2 did include a $243 million share repurchase (30 million shares), its stock-based compensation burden remains high. Full-year stock-based comp is still pegged north of $1.1 billion, even after recent downward revisions. Keep in mind that we're talking about a company with only a $12 billion market cap. Dilution continues to erode per-share value, even as Snap shows cash generation. So while the sell-off may feel overdone, the stock hasn't quite yet fallen low enough to make it a bargain. Of course, I could be wrong. A potential bull case lies not in near-term profits but in optionality -- whether Snap can scale newer revenue streams, stabilize pricing, and get to a point where it doesn't need to regularly materially dilute shareholders. Overall, Snap trades at a valuation that remains questionable given its history of dilution and heavy reliance on noncash compensation. But the emergence of fast-growing subscription revenue, sponsored Snaps, better cash flow, and an engaged user base make it extremely interesting -- worthy of a high spot on any investor's watchlist. Should you buy stock in Snap right now? Before you buy stock in Snap, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Snap wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Daniel Sparks and his clients have no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Snap Stock Plunged After Earnings. Buy the Dip? was originally published by The Motley Fool Sign in to access your portfolio

Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns

Yahoo

time6 minutes ago

  • Yahoo

Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns

Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store